Share

New Cushing’s Syndrome Research Presented at ENDO 2022

The pharmacology data focus on the human body’s homeostatic response to potent HSD-1 inhibition by SPI-62. Results highlight that urinary free cortisol is distinct from intracellular cortisol that causes symptoms in patients with Cushing’s syndrome or autonomous cortisol secretion. Sparrow Pharmaceuticals, a clinical-stage biopharmaceutical company developing novel, targeted therapies to address unmet needs in both endocrinology...
Share

All About Adrenal: Analyzing Two Years of Research

ENDO_2022_4C When the ENDO 2022 session “Clinical Year in Review: All Things Adrenal” gets underway, Gary Hammer, MD, PhD, will treat attendees to the series of advances that have been made in adrenal science and clinical practice over the last two years, from adrenal homeostasis, glucocorticoid biology, and adrenal insufficiency to Cushing’s, tumors, pheochromocytoma, and more....
Share

Gender-Affirming Care: Bridging the Gap

ENDO_2022_4C As transgender medical care becomes unfairly politicized, presentations such as ENDO 2022’s Meet the Professor session “Beginner’s Guide to Gender-Affirming Hormone Therapy for Transgender and Gender Diverse Adults” are more essential than ever. Attendees will be shown a variety of best practices in providing affirming care to transgender and gender diverse adults.   On the...
Share

Phase III LINC 4 Study Confirms Efficacy and Safety of Osilodrostat in Patients with Cushing’s Disease

Positive results from the Phase III LINC 4 study have confirmed the efficacy and safety of osilodrostat, an oral therapy for patients with Cushing’s disease. The results were published in The Journal of Clinical Endocrinology & Metabolism. Recordati Rare Diseases is marketing the drug as ISTURISA®. The LINC 4 study augments the efficacy and safety...
Share

Endocrine-Disrupting Chemicals May Impair Bone Health in Teen Boys

Per- and polyfluoroalkyl substances (PFAS) and phthalates (two types of endocrine-disrupting chemicals) may be associated with lower bone mineral density in male teens, according to a new study published in the Endocrine Society’s Journal of Clinical Endocrinology and Metabolism. Endocrine-disrupting chemicals are chemicals or mixtures of chemicals that interfere with the way the body’s hormones work. Per- and...
Show More

As much as we know today about the endocrine system and the effects it has on the body, there remains so much that we do not know. Discoveries are made every day, and our understanding of the endocrine system is always growing and changing. Serving patients to the best of an endocrinologist’s abilities means being aware of all the latest developments in endocrine research. This includes the newest and most complete information concerning such endocrinology research topics as new treatments and new methods for disease prevention. Identifying symptoms and making the connections between those symptoms and endocrine disease can lead to greater understanding and ultimately better treatment for patients. More advanced prevention techniques can help patients stave off disease before it can impact their lives. Having the most current information can make a tremendous difference in the quality of life for your patients.

This section features some of the most current and forward-looking articles concerning the latest research in endocrinology. Written by and for endocrinologists, these articles are provided to keep you up to date with the most relevant developments in the field of endocrinology. You can access the information you need about new technology, new treatments and general information to help you serve your patients with better overall care. Our understanding of the endocrine system is always evolving. With Endocrine News, you can ensure that your knowledge of the field won’t be left behind. What’s more, your patients will always have access to the most advanced information out there.